Navigation Links
Equol-producer status of US women influences soy food effects on menopause symptoms
Date:11/12/2012

Northridge, Calif. (November 12, 2012) Eating more soy was associated with larger reductions in menopausal vasomotor symptoms (VMS), such as hot flashes, among U.S. women that can convert soy to a compound called equol, according to data from a first-of-its-kind study presented in an oral session at the North American Menopause Society (NAMS) 2012 annual meeting.

"Numerous studies have examined the association between soy isoflavones from both soy foods and supplements - and menopausal VMS, but with mixed results," said Belinda H. Jenks, Ph.D., Director of Scientific Affairs & Nutrition Education at Pharmavite LLC., which funded the prospective observational study. "However, they do not routinely account for whether the enrolled women can produce equol, which has documented reductions on certain VMS such as hot flashes."

The study, conducted by researchers at the Group Health Research Institute, University of Washington and the Fred Hutchinson Cancer Institute, is the first to examine equol production status and the effect of varied soy consumption on VMS in menopausal U.S. women. Evidence from prior observational studies suggests that Japanese women have milder menopausal symptoms in those who are equol producers compared to nonproducers. Additional peer-reviewed studies have documented that dietary supplements containing equol have reduced VMS symptoms in postmenopausal women who are not equol producers.

Equol is produced from the natural metabolism, or conversion, of daidzein, an isoflavone found in whole soybeans. Not everyone can produce equol after soy consumption, as the production depends on the types of bacteria present in the large intestine. About 50 percent of Asians and 20 to 30 percent of North Americans and Europeans, who in general consume less soy than Asians, have the ability to produce equol.

NAMS Study Quantifies VMS Reduction in US Equol Producers

Consuming higher levels of soy containing daidzein was associated with fewer VMS, but only among the women who were equol producers.

Among the 129 equol producers, 36 percent of the study's 355 participants, those consuming the most daidzein in their daily diet, versus those with the least daidzein, were 76 percent more likely to have fewer than the study's daily average number of VMS, 2.33. The positive trend in the equol producers between increased daidzein consumption and reduced VMS symptoms occurred across all four intake levels of daidzein (p=0.06). In comparison, no associations between daidzein intake and VMS were observed in the 229 equol nonproducers.

Investigators grouped all of the women into four levels of soy consumption. The four equol producer groups averaged 28.55, 14.2, 9.01 and 4.88 milligrams of daidzein per day (mg/d) and the average daidzein intake levels in the equol nonproducers were 28.69, 13.76, 8.98 and 4.63 mg/d, which is a range comparable to general soy consumption in Asians.

The researchers also used the Soy-Food Questionnaire to ask women about their diets. This validated tool, developed by Fred Hutchinson Cancer Research Center, poses questions about the consumption of 20 commonly eaten soy foods and supplements to assess soy intake among postmenopausal women in the United States.

The enrolled women averaged 53 years and more than 60 percent were postmenopausal.


'/>"/>
Contact: Stephen McCauley
smccauley@porternovelli.com
202-973-3615
Porter Novelli
Source:Eurekalert

Related medicine news :

1. Better Economic Status Tied to Peanut Allergy in Kids: Study
2. Socioeconomic status linked to childhood peanut allergy
3. Language, immigration status of hispanic caregivers impacted care of children with cancer
4. Childrens health, access to care differ by parents immigrant status
5. Marital status, race increase survival rate significantly for Stage III non-small cell lung cancer patients
6. Study finds non-disclosure of HIV serostatus common among India female sex workers
7. Study examines chronic inflammation in oral cavity and HPV status of head and neck cancers
8. Study finds socioeconomic status linked to weight gain and risk of obesity in African-American women
9. Plavixs New Generic Status Could Be Boon for Patients
10. Disparities in treatment of children in the emergency department based on their insurance status
11. KRAS gene mutation and amplification status affects sensitivity to antifolate therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... PA (PRWEB) , ... December 09, 2016 , ... "I ... Fla. "I used this old family recipe, which is meant to relieve gout and ... it gave me a 12-hour energy boost every time. It relieved what VA doctors ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Holy ... in New York, NY, on December 3rd, to benefit Holy Name Medical Center's ... annual event, which raised over $1 million - the largest event in the ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Florida Hospital ... and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. This accreditation ... a few hospitals and facilities have earned this distinction. This is the second ...
(Date:12/8/2016)... ... December 08, 2016 , ... Mirixa Corporation ... adherence, and other pharmacist-delivered patient care services, has announced the promotions of Karen ... to vice president of sales. , Litsinger joined Mirixa in 2008 after ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView ... customers and employees that are both engaging and easy to use. Coming off ... the software company revealed today its plans to roll out new AI-powered self-service ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Fla. , Dec. 9, 2016  Harmar Mobility, LLC announced ... and a member of the Board of Directors. Photo ... ... Mr. Dawson,s ... development of organizations across a variety of industries. He brings to ...
(Date:12/9/2016)... -- Research and Markets has announced the addition of ... offering. ... global travel vaccines market to grow at a CAGR of 6.83% ... scenario and the growth prospects of the global travel vaccines market ... revenue generated from the sales of various vaccines administered to actively ...
(Date:12/8/2016)... -- IRIDEX Corporation (NASDAQ: IRIX ) today announced ... stock, $0.01 par value (the "Offering" with such shares being ... terms of the Offering will depend on market and other ... no assurance as to whether or when the Offering may ... proceeds it will receive from this offering for working capital ...
Breaking Medicine Technology: